These results are in agreement with those by Liu et al. [47] using anti-CD20 (in hematologic cancers) or anti-HER2 (in solid tumors) therapeutic antibodies. This evidence concerns the gene ERBB2 and hematopoietic and lymphoid cell neoplasm.